These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

489 related articles for article (PubMed ID: 28225674)

  • 1. Inhibiting Plasma Kallikrein for Hereditary Angioedema Prophylaxis.
    Banerji A; Busse P; Shennak M; Lumry W; Davis-Lorton M; Wedner HJ; Jacobs J; Baker J; Bernstein JA; Lockey R; Li HH; Craig T; Cicardi M; Riedl M; Al-Ghazawi A; Soo C; Iarrobino R; Sexton DJ; TenHoor C; Kenniston JA; Faucette R; Still JG; Kushner H; Mensah R; Stevens C; Biedenkapp JC; Chyung Y; Adelman B
    N Engl J Med; 2017 Feb; 376(8):717-728. PubMed ID: 28225674
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of Lanadelumab Compared With Placebo on Prevention of Hereditary Angioedema Attacks: A Randomized Clinical Trial.
    Banerji A; Riedl MA; Bernstein JA; Cicardi M; Longhurst HJ; Zuraw BL; Busse PJ; Anderson J; Magerl M; Martinez-Saguer I; Davis-Lorton M; Zanichelli A; Li HH; Craig T; Jacobs J; Johnston DT; Shapiro R; Yang WH; Lumry WR; Manning ME; Schwartz LB; Shennak M; Soteres D; Zaragoza-Urdaz RH; Gierer S; Smith AM; Tachdjian R; Wedner HJ; Hebert J; Rehman SM; Staubach P; Schranz J; Baptista J; Nothaft W; Maurer M;
    JAMA; 2018 Nov; 320(20):2108-2121. PubMed ID: 30480729
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oral Plasma Kallikrein Inhibitor for Prophylaxis in Hereditary Angioedema.
    Aygören-Pürsün E; Bygum A; Grivcheva-Panovska V; Magerl M; Graff J; Steiner UC; Fain O; Huissoon A; Kinaciyan T; Farkas H; Lleonart R; Longhurst HJ; Rae W; Triggiani M; Aberer W; Cancian M; Zanichelli A; Smith WB; Baeza ML; Du-Thanh A; Gompels M; Gonzalez-Quevedo T; Greve J; Guilarte M; Katelaris C; Dobo S; Cornpropst M; Clemons D; Fang L; Collis P; Sheridan W; Maurer M; Cicardi M
    N Engl J Med; 2018 Jul; 379(4):352-362. PubMed ID: 30044938
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An investigational oral plasma kallikrein inhibitor for on-demand treatment of hereditary angioedema: a two-part, randomised, double-blind, placebo-controlled, crossover phase 2 trial.
    Aygören-Pürsün E; Zanichelli A; Cohn DM; Cancian M; Hakl R; Kinaciyan T; Magerl M; Martinez-Saguer I; Stobiecki M; Farkas H; Kiani-Alikhan S; Grivcheva-Panovska V; Bernstein JA; Li HH; Longhurst HJ; Audhya PK; Smith MD; Yea CM; Maetzel A; Lee DK; Feener EP; Gower R; Lumry WR; Banerji A; Riedl MA; Maurer M
    Lancet; 2023 Feb; 401(10375):458-469. PubMed ID: 36774155
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lanadelumab to treat hereditary angioedema.
    Wedi B
    Drugs Today (Barc); 2019 Jul; 55(7):439-448. PubMed ID: 31347612
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lanadelumab for the Prophylactic Treatment of Hereditary Angioedema with C1 Inhibitor Deficiency: A Review of Preclinical and Phase I Studies.
    Busse PJ; Farkas H; Banerji A; Lumry WR; Longhurst HJ; Sexton DJ; Riedl MA
    BioDrugs; 2019 Feb; 33(1):33-43. PubMed ID: 30539362
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An open-label study to evaluate the long-term safety and efficacy of lanadelumab for prevention of attacks in hereditary angioedema: design of the HELP study extension.
    Riedl MA; Bernstein JA; Craig T; Banerji A; Magerl M; Cicardi M; Longhurst HJ; Shennak MM; Yang WH; Schranz J; Baptista J; Busse PJ
    Clin Transl Allergy; 2017; 7():36. PubMed ID: 29043014
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of avoralstat, an oral kallikrein inhibitor, in a Phase 3 hereditary angioedema prophylaxis trial: The OPuS-2 study.
    Riedl MA; Aygören-Pürsün E; Baker J; Farkas H; Anderson J; Bernstein JA; Bouillet L; Busse P; Manning M; Magerl M; Gompels M; Huissoon AP; Longhurst H; Lumry W; Ritchie B; Shapiro R; Soteres D; Banerji A; Cancian M; Johnston DT; Craig TJ; Launay D; Li HH; Liebhaber M; Nickel T; Offenberger J; Rae W; Schrijvers R; Triggiani M; Wedner HJ; Dobo S; Cornpropst M; Clemons D; Fang L; Collis P; Sheridan WP; Maurer M
    Allergy; 2018 Sep; 73(9):1871-1880. PubMed ID: 29688579
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics, Pharmacodynamics, and Exposure-Response of Lanadelumab for Hereditary Angioedema.
    Wang Y; Marier JF; Kassir N; Chang C; Martin P
    Clin Transl Sci; 2020 Nov; 13(6):1208-1216. PubMed ID: 32407574
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of garadacimab, a factor XIIa inhibitor for hereditary angioedema prevention (VANGUARD): a global, multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
    Craig TJ; Reshef A; Li HH; Jacobs JS; Bernstein JA; Farkas H; Yang WH; Stroes ESG; Ohsawa I; Tachdjian R; Manning ME; Lumry WR; Saguer IM; Aygören-Pürsün E; Ritchie B; Sussman GL; Anderson J; Kawahata K; Suzuki Y; Staubach P; Treudler R; Feuersenger H; Glassman F; Jacobs I; Magerl M
    Lancet; 2023 Apr; 401(10382):1079-1090. PubMed ID: 36868261
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interventions for the long-term prevention of hereditary angioedema attacks.
    Beard N; Frese M; Smertina E; Mere P; Katelaris C; Mills K
    Cochrane Database Syst Rev; 2022 Nov; 11(11):CD013403. PubMed ID: 36326435
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prophylactic use of an anti-activated factor XII monoclonal antibody, garadacimab, for patients with C1-esterase inhibitor-deficient hereditary angioedema: a randomised, double-blind, placebo-controlled, phase 2 trial.
    Craig T; Magerl M; Levy DS; Reshef A; Lumry WR; Martinez-Saguer I; Jacobs JS; Yang WH; Ritchie B; Aygören-Pürsün E; Keith PK; Busse P; Feuersenger H; Pawaskar D; Jacobs I; Pragst I; Doyle MK
    Lancet; 2022 Mar; 399(10328):945-955. PubMed ID: 35219377
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A review of kallikrein inhibitor lanadelumab in hereditary angioedema.
    Hwang G; Johri A; Ng S; Craig T
    Immunotherapy; 2019 Aug; 11(11):937-944. PubMed ID: 31234673
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recombinant human C1 esterase inhibitor for prophylaxis of hereditary angio-oedema: a phase 2, multicentre, randomised, double-blind, placebo-controlled crossover trial.
    Riedl MA; Grivcheva-Panovska V; Moldovan D; Baker J; Yang WH; Giannetti BM; Reshef A; Andrejevic S; Lockey RF; Hakl R; Kivity S; Harper JR; Relan A; Cicardi M
    Lancet; 2017 Sep; 390(10102):1595-1602. PubMed ID: 28754491
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lanadelumab: A Review in Hereditary Angioedema.
    Syed YY
    Drugs; 2019 Nov; 79(16):1777-1784. PubMed ID: 31560114
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lanadelumab for the treatment of hereditary angioedema.
    Wu MA
    Expert Opin Biol Ther; 2019 Dec; 19(12):1233-1245. PubMed ID: 31657963
    [No Abstract]   [Full Text] [Related]  

  • 17. Therapeutic monoclonal antibodies with a focus on hereditary angioedema.
    Zuraw BL; Maurer M; Sexton DJ; Cicardi M
    Allergol Int; 2023 Jan; 72(1):54-62. PubMed ID: 35787344
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oral once-daily berotralstat for the prevention of hereditary angioedema attacks: A randomized, double-blind, placebo-controlled phase 3 trial.
    Zuraw B; Lumry WR; Johnston DT; Aygören-Pürsün E; Banerji A; Bernstein JA; Christiansen SC; Jacobs JS; Sitz KV; Gower RG; Gagnon R; Wedner HJ; Kinaciyan T; Hakl R; Hanzlíková J; Anderson JT; McNeil DL; Fritz SB; Yang WH; Tachdjian R; Busse PJ; Craig TJ; Li HH; Farkas H; Best JM; Clemons D; Cornpropst M; Dobo SM; Iocca HA; Kargl D; Nagy E; Murray SC; Collis P; Sheridan WP; Maurer M; Riedl MA
    J Allergy Clin Immunol; 2021 Jul; 148(1):164-172.e9. PubMed ID: 33098856
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevention of Hereditary Angioedema Attacks with a Subcutaneous C1 Inhibitor.
    Longhurst H; Cicardi M; Craig T; Bork K; Grattan C; Baker J; Li HH; Reshef A; Bonner J; Bernstein JA; Anderson J; Lumry WR; Farkas H; Katelaris CH; Sussman GL; Jacobs J; Riedl M; Manning ME; Hebert J; Keith PK; Kivity S; Neri S; Levy DS; Baeza ML; Nathan R; Schwartz LB; Caballero T; Yang W; Crisan I; Hernandez MD; Hussain I; Tarzi M; Ritchie B; Králíčková P; Guilarte M; Rehman SM; Banerji A; Gower RG; Bensen-Kennedy D; Edelman J; Feuersenger H; Lawo JP; Machnig T; Pawaskar D; Pragst I; Zuraw BL;
    N Engl J Med; 2017 Mar; 376(12):1131-1140. PubMed ID: 28328347
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term prevention of hereditary angioedema attacks with lanadelumab: The HELP OLE Study.
    Banerji A; Bernstein JA; Johnston DT; Lumry WR; Magerl M; Maurer M; Martinez-Saguer I; Zanichelli A; Hao J; Inhaber N; Yu M; Riedl MA;
    Allergy; 2022 Mar; 77(3):979-990. PubMed ID: 34287942
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.